Last reviewed · How we verify
Shanghai WiseGain Medical Devices Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Amlodipine, losartan potassium and hydrochlorothiazide | Amlodipine, losartan potassium and hydrochlorothiazide | phase 3 | Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic) | L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Hanmi Pharmaceutical Company Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai WiseGain Medical Devices Co., Ltd.:
- Shanghai WiseGain Medical Devices Co., Ltd. pipeline updates — RSS
- Shanghai WiseGain Medical Devices Co., Ltd. pipeline updates — Atom
- Shanghai WiseGain Medical Devices Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai WiseGain Medical Devices Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-wisegain-medical-devices-co-ltd. Accessed 2026-05-17.